GDF-15と乳がんにおける治療関連有害事象との関係 (GRADE)
乳癌患者におけるT-DXd治療中のGDF-15レベル変化と治療関連有害事象との関連性を探索する多施設前向コホート研究。
GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd.
GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. There is a link between high GDF-15 levels and the nausea and vomiting experienced with "morning sickness" in pregnancy. It has also been shown that GDF-15 levels will go up with the use of other types of chemotherapy that are known to cause nausea and vomiting.
Side effects such as feeling sick (nausea), vomiting and weight loss are common with T-DXd. Sometimes, these can be so severe that treatment needs to be stopped early. The investigators can't predict who will get bad side effects and who will not.
If the investigators can find out if there is a link between GDF-15 and the side effects of T-DXd, they can use this information in future clinical trials.
調査の概要
詳細な説明
Growth differentiation factor 15 (GDF-15), a stress-related hormone also known as macrophage inhibitory cytokine-1 (MIC-1), is a member of the transforming growth factor-beta (TGF-β) superfamily. It is not expressed under basal conditions but can be released in response to pro-inflammatory conditions such as obesity, insulin resistance, renal and heart failure, and malignancy.
Pre-clinical studies have established the role of elevated GDF-15 levels in tumour and platinum-based chemotherapy induced emesis and cachexia. It has also been proposed as a biomarker for all-cause mortality, as well as for poor prognoses in patients with cancer.
The hypothesis is that there is a positive correlation between increased levels of GDF-15 and the severity of treatment-related adverse events (particularly nausea, vomiting and cachexia) experienced by patients with breast cancer receiving T-DXd.
The aim of the study is to explore the relationship between relative change in levels of GDF-15 from baseline (pre-treatment) to after receiving T-DXd (post-C2 and at end of treatment) and the severity of treatment-related adverse events experienced by patients with breast cancer receiving T-DXd.
If a positive relationship is found with any or all of these objectives, then monoclonal antibodies inhibiting GDF-15 (such as ponsegromab or visugromab) may present a promising therapeutic and supportive option for patients receiving T-DXd.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Tracey Hay
- 電話番号:+61 (0) 2 4925 5277
- メール:tracey.hay@bctrials.org.au
研究連絡先のバックアップ
- 名前:Michelle Li, Dr
- 電話番号:+61 (0) 3 8559 5935
- メール:michelle.li@petermac.org
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
コンタクト:
- Michelle Li, Dr
- 電話番号:+61 (0) 3 8559 5935
- メール:michelle.li@petermac.org
-
主任研究者:
- Michelle Li, Dr
-
-
-
-
New South Wales
-
Newcastle、New South Wales、オーストラリア、2290
- Lake Macquarie Private Hospital
-
コンタクト:
- Nick Zdenkowski, Dr
- 電話番号:+61 (02) 4942-2600
- メール:nick.zdenkowski@newcastle.edu.au
-
主任研究者:
- Nick Zdenkowski, Dr
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3000
- Peter MacCallum Cancer Centre
-
コンタクト:
- Sherene Loi, Prof
- 電話番号:+61 (03) 8559-5935
- メール:sherene.loi@petermac.org
-
主任研究者:
- Sherene Loi, Prof
-
-
-
-
-
Okayama、日本、700-8558
- Okayama University Hospital
-
コンタクト:
- Tadahiko Shien, Prof
- 電話番号:+81 (08) 62357265
- メール:tshien@md.okayam-u.ac.jp
-
主任研究者:
- Tadahiko Shien, Prof
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants aged ≥18 years.
- Histologically confirmed diagnosis of metastatic/advanced unresectable HER2-positive or HER2-low breast cancer.
- Planned to start treatment with T-DXd.
- Life expectancy of at least 4 months.
Exclusion Criteria:
- Current active reversible causes of decreased food intake, as determined by the Investigator.
- Receiving tube feedings or any kind of parenteral nutrition at the time of enrolment into the study.
- Ongoing cachexia attributable to other reasons unrelated to cancer or cancer treatment as determined by the Investigator that may confound interpretation of weight loss due to T-DXd.
- Current adherence to a calorie-restricted diet with the intention of weight loss.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Blood Collection for GDF-15
Blood collection for GDF-15 during T-DXd treatment. |
Blood samples of 20-30mL (approximately 1-2 tablespoons in total) will be taken 4 times:
At each blood collection, participants will be asked about:
Personal and health information will also be collected from participants:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Nausea prior to Cycle 3 of T-DXd, graded according to Common Terminology Criteria for Adverse Advents (CTCAE) v5.0.
時間枠:From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade nausea (CTCAE Grade 2-4) experienced at this timepoint by patients with metastatic/advanced unresectable HER2-positive or HER2-low breast cancer. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vomiting prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
時間枠:From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade vomiting (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Weight loss (cachexia) prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
時間枠:From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade cachexia (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Percentage change in GDF-15 and its correlation with treatment-related adverse events (TRAEs)
時間枠:From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To explore the correlation of the percentage change in levels of GDF-15 with the treatment-related adverse events (CTCAE Grade 2-4). Treatment-related adverse events (TRAEs) are adverse events classified as possibly, probably or definitely related to T-DXd treatment. TRAEs will be graded as per CTCAE v5.0. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Progression-free survival (PFS)
時間枠:Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and progression-free survival (PFS) on T-DXd |
Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
|
Time to treatment failure (TTF)
時間枠:Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and time to treatment failure (TTF) on T-DXd. |
Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
|
HER2 copy number
時間枠:Prior to treatment commencement.
|
To explore the relationship between HER2 copy number and change in levels of GDF-15. HER2 copy number determined by in-situ hybridization (ISH) on most recent available histopathology specimen or tumour/plasma genomic data (DNA/RNA), preferably in the metastatic setting |
Prior to treatment commencement.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory: Association of baseline levels of GDF-15 with Treatment Related Adverse Events (TRAEs).
時間枠:TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
To explore if baseline levels of GDF-15 are associated with the incidence and severity of TRAEs experienced by patients on T-DXd, graded as per CTCAE v5.0. |
TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight after 2 cycles of T-DXd
時間枠:After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
To explore if the longitudinal change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. End-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity. |
After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight at end-of-treatment
時間枠:At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
To explore if the longitudinal change in levels of GDF-15 from baseline at end-of-treatment with T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. |
At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
協力者と研究者
捜査官
- スタディディレクター:Heath Badger、Breast Cancer Trials, Australia and New Zealand
- スタディチェア:Sherene Loi, Prof、Peter MacCallum Cancer Centre, Australia
- スタディチェア:Michelle Li, Dr、Peter MacCallum Cancer Centre, Australia
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BCT 2502
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymised Individual Patient Data (IPD) collected during the trial.
IPD 共有時間枠
Data will be made available for request after publication of the main/final study results; no end date.
IPD 共有アクセス基準
Researchers who submit a research proposal and BCT Data Request Application, which is assessed by BCT to have appropriate scientific value. Applications will be subject to approval by Breast Cancer Trials concept@bctrials.org.au (refer to BCT Data Sharing Guidelines).
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。